Rigel Pharmaceuticals (RIGL) vs Seaport Therapeutics (SPTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Seaport Therapeutics is the larger company by market cap ($959.8 million vs $896.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RIGL | SPTX |
|---|---|---|
| Share price | $47.99 | $17.93 |
| Market cap | $896.45M | $959.80M |
| 1-day change | +4.08% | +3.22% |
| YTD return | +12.05% | — |
| 1-year return | +62.68% | — |
| 5-year return | +41.98% | — |
| P/E ratio (TTM) | 2.84 | — |
| Forward P/E | 9.72 | — |
| EPS (TTM) | $16.88 | $-5.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.24 | $28.38 |
| 52-week low | $24.95 | $14.85 |
| Distance from 52-week high | -8.14% | -36.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +31.28% | +113.55% |
| Average volume | 291.58K | 181.78K |
| Shares outstanding | 18.68M | 53.53M |
| Employees | 172 | 58 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Rigel Pharmaceuticals
RIGL stock →Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
Healthcare · Biotechnology · 172 employees
About Seaport Therapeutics
SPTX stock →Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Healthcare · Biotechnology · 58 employees
RIGL vs SPTX FAQ
Which is bigger, Rigel Pharmaceuticals or Seaport Therapeutics?
Seaport Therapeutics (SPTX) is larger, with a market capitalization of $959.80M compared with $896.45M for Rigel Pharmaceuticals (RIGL).
Are Rigel Pharmaceuticals and Seaport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.